510(k) Submissions Workshop
Virtual Event
February 22 - 23, 2021
*Schedule Reflected in Eastern Time

Feb 22, 2021

11:00 – 11:05 am Welcome and Introductions

11:05 am – 12:20 pm The Law and Regulations
Sally Maher, Maher Consulting Group
- 510(k) definition
- 510 and 513 FDCA
- Guidance for 510(k): general & product specific
  - How to find it
  - How to use it
- Different types of 510(k)s; which to use
- Review of bundling 510(k)s
- CDRH organizational structure
- FDA Product Codes - activity

12:20 – 12:25 pm Break

12:25 – 1:40 pm 510(k) Strategy and Planning
Sally Maher, Maher Consulting Group
- Staff involved
- Role of each function
- RA responsibilities
- Use of guidance
- Global considerations
- Pre-submissions
- Predicates

1:40 – 1:50 pm Break

1:50 – 3:20 pm Preparing the Submission
Wil Henderson, Hogan Lovells
- General information including how to select a predicate device
- Assembling the 510(k)
- eCopy
- 510(k) Interactive Exercise

3:20 – 3:25 pm Break

Important Notice
The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.
The FDA Review Process

Angela DeMarco, FDA
- How it works at FDA
- FDA/industry interactions
- Refuse to Accept
- Submission Issue meetings
- FDA holds
- Interactive review
- Least Burdensome flag
- Current pilots

Feb 23, 2021

11:00 – 12:30 pm
Clearance: Launch and After

Tony Blank, Infinity Biomedical Group
- What clearance does and does not mean
- Promotional practices for 510(k) devices
  - FDA
  - FTC
- Complaint Handling and MDRs

12:30 – 12:35 pm
Break

12:35 – 1:05 pm
When to File a New 510(k) for Device Modifications

Tony Blank, Infinity Biomedical Group
- Catch-up 510(k)s

1:05 – 1:25 pm
510(k) Post-Clearance Exercise

Quynh Hoang, King & Spalding

1:25 – 1:35 pm
Break

1:35 – 2:35 pm
De Novo

Peter Yang, FDA
- Definition of a De Novo
- When De Novo is used
- Differentiation from 510(k)
- Format
- Use of pre-sub
- Post market requirements
- Use as a predicate

Important Notice
The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.
2:35 – 2:40 pm          Break

2:40 – 3:25 pm          Regulatory Strategy for De Novo
                        Holly Drake, Dexcom
                        • Key eligibility criteria
                        • Benefit-risk analysis
                        • Case example

3:25 – 4:10 pm          CDRH Ombudsman’s Office – Roles & Responsibilities and the Appeals Process
                        Ken Skodacek, FDA

4:10 – 4:15 pm          Closing Remarks and Adjourn

Important Notice
The information provided in this course represents the personal opinions of the instructors and does not necessarily represent
the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any
subsequent liability that results from relying on the information. The information does not constitute legal advice.